Heart failure & cardiomyopathiesCohort study
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes
- cohort
- inverse probability treatment weighting
- time-dependent Cox models
Authors' conclusion
Significant TR portends worse prognosis in HF. SGLT2i therapy is associated with improved outcomes and attenuated TR progression in this high-risk population, with findings limited by the observational design and potential residual confounding.
Study context
- Population
- Patients with heart failure (HF) (2014–2024) who underwent echocardiography within 90 days of diagnosisHF patients, 4043 (14%) had significant tricuspid regurgitation (TR), 2320 (8%) received SGLT2i
- Participants
- 28,940 patients
- Exposure
- Patients were stratified by significant TR and SGLT2i use
- Significant TRn = 4,043
- SGLT2in = 2,320
- Outcome
- Composite of:
- All-cause mortality
- HF hospitalization
- Follow-up
- Median 3.5 years (IQR 1-7)
Main finding
As reported in the abstract
Adjusted hazard ratio (95% CI)P value
Significant TRworse outcomes
1.21(1.14–1.28)
P < 0.001SGLT2ilower event rates
0.79(0.69–0.92)
P = 0.002- Patients experiencing the primary outcome
- 11 646 (40%)
- SGLT2i aHR with significant TR
- 0.65
- SGLT2i aHR without significant TR
- 0.83
Observational data: associations, not effects.
Secondary outcomes
TR progression (secondary outcome)
- SGLT2i associated with reduced risk for TR progression
- 28%
- 95% CI
- 0.58-0.90
- P
- P < 0.001
HF subtypes and sensitivity analyses
- Results were consistent across HF subtypes and sensitivity analyses
Original publication
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes. Eur Heart J Cardiovasc Pharmacother. Published 30 March 2026. doi:10.1093/ehjcvp/pvag018
Summarised from the published abstract; every number is checked against it